Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placeboCHICAGO, Jan. 11, 2023 /PRNewswire/ --...

Related Keywords

United States ,Cincinnati ,Ohio ,Chicago ,Illinois ,America ,Donald Gilbert ,Sheridan Chaney ,Emalex Biosciences ,Emalex Biosciences Inc About Ecopipam ,Paragon Biosciences ,Yale Global Tourette Severity Total Tic ,Clinical Global Impression ,Tourette Syndrome Severity ,North America ,Cincinnati Children ,Emalex Biosciences Inc About ,Orphan Drug ,Fast Track ,About Paragon Biosciences ,